• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

GE installs flat panel SPECT/CT

Article

Other headlinesAmicas revenues, losses growNightHawk revenues rise

GE installs flat panel SPECT/CT
The first installations of GE Healthcare’s new direct digital SPECT/CT gamma camera are in place at Rambam Medical Center in Haifa, Israel, and University Hospital in Zurich, Switzerland. The dedicated cardiology systems, dubbed Discovery NM/CT 570c, feature GE’s proprietary Alcyone Technology, which is built around a cadmium zinc telluride (CZT) detector.  Combined with GE’s LightSpeed VCT, the CZT-based gamma camera hybrid can acquire data for a complete cardiac scan in less than five minutes , delivering results for myocardial perfusion imaging, attenuation correction, CT angiography, and calcium scoring. 
 
Amicas revenues, losses grow
Revenues grew substantially last quarter at PACS/IT vendor Amicas  to $23.5 million compared with  $13.6 million in the second quarter, but the company still wrote its bottom line in red. Operating loss for the second quarter of 2009 was $6.6 million compared with an operating loss of $0.6 million for year earlier period. Not included in the totals were $4.0 million, revenues not recognized under GAAP due to purchase accounting treatment related to the company's acquisition of Emageon. In its quarterly report, the company noted  best-ever bookings and revenue and accelerated progress on its integration of Emageon, which was acquired early in 2009. 

NightHawk revenues rise
NightHawk Radiology did better than expected last quarter, beating consensus expectations with $42.3 million in revenue, up 9% from those of the previous quarter. GAAP net income was $2.1 million. The company reported a big increase in readings from existing customers and also signed a record number of new radiology groups and hospitals, according to Nighthawk CEO Dave Engert.  In the near term, 30% of all radiology readings will be done remotely, Engert said. Revenue in the quarter ahead will be close to or nearly flat, ranging between $42 million and $43 million.

 

 

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.